Botulinum Toxin Market Research Report - Forecast till 2030

Botulinum Toxin Market Research Report: Information By Product (Botulinum Toxin A and Botulinum Toxin B), By Application (Medical and Aesthetic), By Gender (Female and Male), By Age Group (13-19, 20-29, 30-39, 40-54, and 55 & Above), By End User (Hospitals, Dermatology Clinics, and Spas & Cosmetic Centers), and Region (North America, Europe, Asia-Pacific, and Rest of the World)—Forecast till 2030

ID: MRFR/HC/7095-CR | February 2021 | Region: Global | 151 Pages         

Botulinum Toxin Market

Botulinum Toxin Market is expected to reach USD 6.5 Billion at CAGR of 11.80% during the forecast period 2022-2030

Segmentation

By Type Botulinum Toxin A and Botulinum Toxin B
Application Aesthetic and Therapeutic
End User Dermatology Centers Hospitals and Clinics and others

Key Players

  • Allergan PLC
  • Galderma S.A.
  • Merz Pharma GmbH & Co KGaA
  • Ipsen Pharma
  • Medytox

Drivers

  • increasing demand for cosmetic surgeries and non-invasive procedures
  • increasing cases of cervical dystonia
Speak to Analyst Request a Free Sample

Botulinum Toxin Market Overview


The botulinum toxin market size was valued USD 3.3 billion and is projected to reach USD 6.5 billion by 2030 at 11.80% CAGR during the forecast period 2022-2030.


Botulinum toxin is released from the clostridium botulinum organism which is responsible for the deadly poisoning condition known as botulism. This botulinum neurotoxin contains eight different subtypes named A, B, C1, C2, D, E, F, and G. This toxin is preferred as an effective mode of treatment for cosmetic and several therapeutic indications like cervical dystonia, spasticity, and chronic migraine.


According to the American Society of Plastic Surgeons, there is an increase in the number of minimally invasive cosmetic procedures by nearly 200 % from the year 2000 without any slowdown. From the market overview, it is clear that there is an increase in the importance of aesthetic beauty in the market which increases the demand for the botulinum toxin market in the assessment period. 


COVID-19 Analysis:


The COVID-19 pandemic is adversely impacted on various sectors like automobiles, education, transportation, electrical & electronics, food& beverages, healthcare, and many more. Majorly it is clear that the healthcare sector is drastically impacted as it acts as a central part of this unprecedented pandemic challenge. This pandemic also severely impacted the botulinum toxin market globally by the reduction of demand in both therapeutic and aesthetic applications. The stringent regulations imposed by the government like lockdowns, supply chain disruptions, and elective procedures ban are the major factors to decline the demand for botulinum toxin products.


A few therapeutic indications were stopped treatment which leads to accessing emergency departments have been treated with this protein. Thus the toxin for the treatment of the critical conditions has continued. In the second quarter of the financial year, the major key players are reporting that there was a decline in the revenue from the neurotoxin preparations. One of the strong key players, Allergan reported a decline in revenue of 43.1% and 22.3% compared to the previous year’s revenue for Botox cosmetic and botox therapeutic. Due to the closure of the treatments center, there is a decline in the revenue of botulinum toxin products.   


Market Dynamics:


Drivers:


Over the past decade, people are choosing easy and painless methods to look young and healthy without the problem of invasive cosmetic surgery. Due to this reason, the demand for cosmetic surgeries and non-invasive procedures is increasing which is propelling the growth of the botulinum toxin treatment.


The surge in demand for facial aesthetics is one of the major factors that drive market growth. The increasing cases of cervical dystonia, spasticity, and chronic migraine is boosting the botulinum toxin market growth. Rising affordability and amendment in reimbursement policies to improve the benefits of botulinum injections are escalating the growth of the spasticity treatment market.


Restraint:


The botox is very expensive which is restraining the market growth. Due to various therapeutic and medical aesthetic applications of botulinum toxin, there is a chance of affecting various side effects by using this protein is hindering the growth of the botulinum toxin structure.


Opportunities:


The growing product launches and approvals by the prominent key players are predicted to accelerate the growth of botulinum toxin therapy in the coming years.


Challenges:


There is a possibility of causing harmful effects by the use of these toxins injections. Swelling or bruising at the injection site, pain, headache or flu-like symptoms, crooked smile or drooling droopy eyelid, or cockeyed eyebrows, and eye dryness or excessive tearing are the possible adverse botulinum toxin effects caused. These botulinum toxin symptoms are very harmful to the human body. The poor reimbursement policies of the botulinum toxin market are expected to limit the botox market growth. 


Study Objectives



  • To provide detailed information about the market structure along with various forecast segments and subsegments for the next 10 years.

  • To provide the factors that are affecting the growth of the market value.

  • To analyze the market analysis based on porter’s five force analysis, factors-price analysis, supply chain analysis, etc.

  • To provide history and forecast revenue segments and sub-segments of the botulinum toxin market revenue for the main geographies.

  • To provide the country-level analysis of the current market size and future prospective.

  • To provide country-level analysis of the market industry growth by region, form, and application.

  • To provide a strategic profile of the prominent key players in the market, analyze their core competencies, and draw a global market growth landscape.

  • To track and analyze new product developments, strategic alliances, and global market research.


Botulinum Toxin Global Market Share, 2018 (%)  


Source: MRFR Analysis


Segment Overview


The global botulinum toxin market has been divided into segments based on type, application, end-user, and region.


Based on Type


By type, the global botulinum toxin market is categorized into botulinum toxin types A and B. Out of these two types, botulinum toxin type A holds a significant market share of 96.29% for its high usage in the market. Botulinum toxin type A products are highly available in the market. The leading brands of botulinum toxin type A are Dysport (Galderma SA), Botox (Allergan), and Xeomin (Merz Pharma GmbH & Co KGaA) that are holding maximum share in the global market.


Based on Application


The botulinum toxin global market based on the application is bifurcated into two types as therapeutic and aesthetic applications. Further, the therapeutic segment is divided into spasticity, chronic migraine, overactive bladder, cervical dystonia, blepharospasm, and others. Among them, the therapeutic application is dominating the botulinum toxin market share due to the heavy investments for extensive research & development and it is widely applied in various disease categories.


Based on End-user


The botulinum toxin global market based on the end-user is classified into dermatology centers, hospitals & clinics, and others. Among them, the hospitals & clinics segment is dominating the botox market share.


Based on Region


Regionally, the botulinum toxin global market is analyzed into four main geographies such as Europe, Asia-Pacific, America, and the Middle East & Africa. Out of these regions, America is dominating the largest botulinum toxin market share for the presence of major manufacturers, rising product approvals, and increasing cases of spasticity.


Regional Analysis


Geographically, the botulinum toxin global market based on regions is divided into four major regions like Asia-Pacific, Europe, America, and the Middle East & Africa. Among them, America is holding the largest market share due to the rising product approvals, increasing cases of spasticity, and the presence of major manufacturers like LLC., WorldMeds, Evolus, Inc., Hugel, Inc., and Revance Therapeutics, Inc., These factors are increasing the botulinum toxin market in this region.


Due to the growing botulinum toxin procedures and the presence of developed economies like the UK, France, and Germany, Europe is holding the second-largest share in the botulinum toxin market. In 2018, in Germany, nearly 321,702 botulinum toxic procedures were carried according to the International Society of Aesthetic Plastic Surgery. Asia-Pacific is expected to be the fastest-growing region due to the rising geriatric population, growing per capita disposable income, developing healthcare infrastructure, medical tourism, and booming entertainment industry. According to the United Nations Population Fund(UNFPA), over the age of 60 populations share was 8% in 2015 and is expected to reach 19% by 2050. Due to the presence of well-developed healthcare sectors, the Middle East & Africa is holding the lowest market share.


Competitive Landscape


The prominent key players in the botulinum toxin market outlook are the following:



  • Daewoong Pharmaceutical Co., Ltd

  • AllerganPLC

  • Galderma S.A.,

  • Merz Pharma GmbH & Co KGaA

  • Ipsen Pharma

  • US WorldMeds, LLC

  • Evolus, Inc.,

  • Hugel, Inc.,

  • Medytox

  • Revance Therapeutics, Inc.


Recent Developments


In September 2019, one of the leading key players, Medytox introduced a botulinum toxin product, Coretox which reduces the risk of resistance to extend its product portfolio.


In September 2019, the most popular enterpriser, Ipsen Pharma announced that Dysport (abobotulinumtoxinA) got the FDA approval for the treatment of lower limb spasticity in pediatric patients of age 2 to 17 group. This approval is predicted to accelerate the botulinum toxin market sales.


In March 2018, the famous German-based aesthetics and neurotoxin vendor, Merz Pharma GmbH & Co KGaA belonging product Xeomin (Incobotulinumtoxina) were US FDA-approved the supplemental biologics license application. This product is used for treating sialorrhea in adult patients.


Report Overview:


This global botulinum toxin market research includes the Market Overview, COVID-19 analysis, Market Dynamics, Study Objectives, Segment Overview, Regional Analysis, Competitive Landscape, Recent developments, Segmentation Table, and FAQs. The market scenario includes the market drivers, restraints, challenges, and opportunities. The botulinum toxin global market forecast segments are type, application, end-user, and region.


Segmentation Table


The botulinum toxin market trends have been segmented into four types, globally based on the type, application, end-user, and region.


By Type


Botulinum toxin type A and B.


By Application


Therapeutic and aesthetic applications.


By End-user


Dermatology centers, hospitals & clinics, and others.


By Region


Asia-Pacific, Europe, North America, and the rest of the world are the four main geographies included in the market.



Report Scope:

Report Attribute/Metric Details
  Market Size   2030: USD 6.5 billion
  CAGR   11.80% CAGR (2022-2030)
  Base Year   2021
  Forecast Period   2022-2030
  Historical Data   2020
  Forecast Units   Value (USD Billion)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Product, Application, Gender, Age Group, and End-User
  Geographies Covered   North America, Europe, Asia-Pacific, and the Rest of the World (RoW)
  Key Vendors   AbbVie Inc, Eisai Co., Ltd., Evolus Inc, Galderma, Hugel, Inc., and Hugh Source International Ltd
  Key Market Opportunities   Increasing R&D initiatives and the growing number of therapeutic and aesthetic indications
  Key Market Drivers   The surge in demand for minimally-invasive cosmetic procedures


Speak to Analyst Ask for Customization

Frequently Asked Questions (FAQ) :

The valuation was USD 6,500 Million in 2030.

Daewoong Pharmaceutical Co., Ltd, Allergan PLC, Galderma S.A., Merz Pharma GmbH & Co KGaA, Ipsen Pharma, US WorldMeds, LLC, Evolus, Inc., Hugel, Inc., Medytox, Revance Therapeutics, Inc are the key players in the market

The better expansion scope is for the aesthetic segment.

The hospitals segment has the market lead.